NASDAQ:MRVI Maravai LifeSciences (MRVI) Stock Price, News & Analysis $5.37 -0.06 (-1.10%) (As of 12/20/2024 05:40 PM ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends About Maravai LifeSciences Stock (NASDAQ:MRVI) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Maravai LifeSciences alerts:Sign Up Key Stats Today's Range$5.32▼$5.6250-Day Range$4.42▼$8.5052-Week Range$4.28▼$11.56Volume2.47 million shsAverage Volume2.22 million shsMarket Capitalization$1.36 billionP/E RatioN/ADividend YieldN/APrice Target$10.28Consensus RatingHold Company OverviewMaravai LifeSciences Holdings, Inc., a life sciences company, provides products to enable the development of drug therapies, diagnostics, novel vaccines, and support research on human diseases worldwide. The company's products address the key phases of biopharmaceutical development and include nucleic acids for diagnostic and therapeutic applications, antibody-based products to detect impurities during the production of biopharmaceutical products, and products to detect the expression of proteins in tissues of various species. It operates in two segments, Nucleic Acid Production and Biologics Safety Testing. The Nucleic Acid Production segment manufactures and sells products for use in the fields of gene therapy, vaccines, nucleoside chemistry, oligonucleotide therapy, and molecular diagnostics, including reagents used in the chemical synthesis, modification, labelling, and purification of deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). This segment also offers messenger RNA, oligonucleotides, and oligonucleotide building blocks, as well as custom enzyme development and manufacturing and CleanCap capping technology. The Biologics Safety Testing segment sells analytical products for use in biologic manufacturing process development, including custom product-specific development antibody, and assay development services. This segment also provides HCP ELISA kits, other bioprocess impurity and contaminant ELISA kits, ancillary reagents, viral clearance prediction kits, and custom services. The company serves biopharmaceutical companies, and other biopharmaceutical and life sciences research companies; and academic research institutions and in vitro diagnostics companies. The company was incorporated in 2020 and is headquartered in San Diego, California.Read More… Maravai LifeSciences Stock Analysis - MarketRank™See Top Rated MarketRank™ Stocks88th Percentile Overall ScoreMRVI MarketRank™: Maravai LifeSciences scored higher than 88% of companies evaluated by MarketBeat, and ranked 121st out of 945 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingMaravai LifeSciences has received a consensus rating of Hold. The company's average rating score is 2.36, and is based on 5 buy ratings, 5 hold ratings, and 1 sell rating.Amount of Analyst CoverageMaravai LifeSciences has been the subject of 6 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Maravai LifeSciences' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Maravai LifeSciences are expected to grow in the coming year, from ($0.24) to ($0.20) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Maravai LifeSciences is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Maravai LifeSciences is -3.27, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioMaravai LifeSciences has a P/B Ratio of 1.71. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted3.13% of the outstanding shares of Maravai LifeSciences have been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 13.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldMaravai LifeSciences does not currently pay a dividend.Dividend GrowthMaravai LifeSciences does not have a long track record of dividend growth. Sustainability and ESG4.4 / 5Environmental Score-1.23 Percentage of Shares Shorted3.13% of the outstanding shares of Maravai LifeSciences have been sold short.Short Interest Ratio / Days to CoverMaravai LifeSciences has a short interest ratio ("days to cover") of 4.4.Change versus previous monthShort interest in Maravai LifeSciences has recently increased by 13.51%, indicating that investor sentiment is decreasing significantly. News and Social Media2.0 / 5News Sentiment0.62 News SentimentMaravai LifeSciences has a news sentiment score of 0.62. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Medical companies.News Coverage This WeekMarketBeat has tracked 8 news articles for Maravai LifeSciences this week, compared to 4 articles on an average week. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Maravai LifeSciences insiders have bought more of their company's stock than they have sold. Specifically, they have bought $987,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 0.63% of the stock of Maravai LifeSciences is held by insiders.Percentage Held by Institutions50.25% of the stock of Maravai LifeSciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Maravai LifeSciences' insider trading history. Receive MRVI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Maravai LifeSciences and its competitors with MarketBeat's FREE daily newsletter. Email Address MRVI Stock News HeadlinesMaravai Lifesciences initiated with a Neutral at GuggenheimDecember 20 at 8:40 AM | finance.yahoo.comAnalysts Set Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) PT at $10.28December 20 at 1:31 AM | americanbankingnews.comForced out of retirement by these trades You know, I never really intended to get in front of a camera and tell folks about a new market paradigm that I discovered. Even though I have a bright and shiny “resume,” I thought I’d left investing behind forever. And I was more than happy to be a stay-at-home dad… But then I discovered Gamma Pockets… and everything changedDecember 22, 2024 | DTI (Ad)Danaher, Cryoport, Sartorius win Buy as Guggenheim expands bioprocessing coverageDecember 19 at 7:49 PM | msn.comCraig-Hallum Sticks to Their Buy Rating for Maravai Lifesciences Holdings (MRVI)December 6, 2024 | markets.businessinsider.comGoldman Sachs Downgrades Maravai LifeSciences Holdings (MRVI)December 6, 2024 | msn.comMaravai LifeSciences Appoints R. Andrew Eckert as Chairman of the Board of DirectorsDecember 5, 2024 | globenewswire.comMaravai LifeSciences: Still Struggling To Find Its FootingNovember 25, 2024 | seekingalpha.comSee More Headlines MRVI Stock Analysis - Frequently Asked Questions How have MRVI shares performed this year? Maravai LifeSciences' stock was trading at $6.55 on January 1st, 2024. Since then, MRVI shares have decreased by 18.0% and is now trading at $5.37. View the best growth stocks for 2024 here. How were Maravai LifeSciences' earnings last quarter? Maravai LifeSciences Holdings, Inc. (NASDAQ:MRVI) issued its quarterly earnings data on Wednesday, August, 7th. The company reported ($0.08) earnings per share for the quarter. The company's revenue for the quarter was up 6.5% on a year-over-year basis. When did Maravai LifeSciences IPO? Maravai LifeSciences (MRVI) raised $1.3 billion in an IPO on Friday, November 20th 2020. The company issued 50,000,000 shares at a price of $24.00-$27.00 per share. Morgan Stanley, Jefferies and Goldman Sachs acted as the underwriters for the IPO and BofA Securities, Credit Suisse, UBS Investment Bank, Baird, William Blair, Stifel, Keybanc Securities, Academy Securities, Loop Capital Markets, Penserra Securities and Tigress Financial Partners were co-managers. Who are Maravai LifeSciences' major shareholders? Top institutional shareholders of Maravai LifeSciences include Braidwell LP (3.31%), Massachusetts Financial Services Co. MA (1.43%), Jennison Associates LLC (1.18%) and Geode Capital Management LLC (1.09%). Insiders that own company stock include Gtcr Investment Xi Llc and Carl Hull. View institutional ownership trends. How do I buy shares of Maravai LifeSciences? Shares of MRVI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Maravai LifeSciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Maravai LifeSciences investors own include Waste Connections (WCN), American Water Works (AWK), The RMR Group (RMR), DiamondRock Hospitality (DRH), AUO (AUOTY), iShares Micro-Cap ETF (IWC) and Triple Flag Precious Metals (TFPM). Company Calendar Last Earnings8/07/2024Today12/22/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:MRVI CUSIPN/A CIK1823239 Webwww.maravai.com Phone858-546-0004FaxN/AEmployees580Year FoundedN/APrice Target and Rating Average Stock Price Target$10.28 High Stock Price Target$15.00 Low Stock Price Target$4.25 Potential Upside/Downside+91.5%Consensus RatingHold Rating Score (0-4)2.36 Research Coverage11 Analysts Profitability EPS (Most Recent Fiscal Year)($1.64) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-119,030,000.00 Net Margins-81.13% Pretax Margin159.33% Return on Equity-6.61% Return on Assets-3.45% Debt Debt-to-Equity Ratio0.89 Current Ratio10.74 Quick Ratio9.94 Sales & Book Value Annual Sales$276.92 million Price / Sales4.90 Cash Flow$0.09 per share Price / Cash Flow59.87 Book Value$3.14 per share Price / Book1.71Miscellaneous Outstanding Shares252,528,000Free Float250,937,000Market Cap$1.36 billion OptionableOptionable Beta-0.08 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report This page (NASDAQ:MRVI) was last updated on 12/22/2024 by MarketBeat.com Staff From Our PartnersCould This Tiny Device Help You Make an Extra $30k a Year?I believe it’s going to power Elon Musk’s next AI revolution… A revolution he believes will be worth more t...Brownstone Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Starting with what I call Exec. Order 001. It’s a bombshell law that I believe Trump will sign within minut...Banyan Hill Publishing | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowAltcoin season moves fast, and those who hesitate are left behind. The window is closing.Crypto Swap Profits | SponsoredEven Trump can’t stop what’s coming.No matter who sits in the White House over the next four years, a series of events has been triggered that cou...Behind the Markets | SponsoredSeeing is believing… Today, I want to share all the details with you… and show you how to leverage this incredible wealth-building ...Porter & Company | Sponsored2025’s #1 Trump TradeAll the Energy You Need to Power Your Entire Life... Could Fit Inside This Single Soda Can. Three Companies...The Oxford Club | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredHOTTEST TRADER IN AMERICA 🔥🔥🔥Ready for a rocket ride this weekend? After alerting his readers to a tiny $2 stock called Bright Minds Bio...Timothy Sykes | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Maravai LifeSciences Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Maravai LifeSciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.